Watson David O. - 07 Jan 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
General Counsel
Signature
David Watson
Issuer symbol
APLS
Transactions as of
07 Jan 2026
Net transactions value
+$13,276
Form type
4
Filing time
09 Jan 2026, 18:48:43 UTC
Previous filing
18 Dec 2025
Next filing
15 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Watson David O. General Counsel C/O APELLIS PHARMACEUTICALS, INC, 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM David Watson 09 Jan 2026 0001657719

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $13,276 +888 +0.86% $14.95 104,618 07 Jan 2026 Direct
holding APLS Common Stock 10,000 07 Jan 2026 Indirect Owner (Custodial Account for minor children) F1
holding APLS Common Stock 50,136 07 Jan 2026 Indirect Owner (The David O. Watson Irrevocable Trust of 2023) F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -888 -6% $0.000000 14,000 07 Jan 2026 Common Stock 888 $14.95 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This represents a custodial account held by the reporting person for the sole benefit of his minor children.
F2 The securities are held by The David O. Watson Irrevocable Trust of 2023. William Zorn is the trustee of The David O. Watson Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The David O. Watson Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
F3 This option was granted on February 16, 2018 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.